Several prospective randomized trials have established the benefit of the dual EGFR/VEGF pathway on PFS in advanced EGFR-mutant NSCLC (Nakagawa et al., 2019; Zhou et al., 2019; Makoto et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.